Adalimumab-bwwd Solution
Product Images NDC 83457-186

Product Visual Gallery

This gallery contains 63 technical images submitted to the FDA as part of the official labeling for Adalimumab-bwwd (NDC 83457-186). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cordavis Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line graph comparing the percentage of ACR20 responders over time (weeks) between two groups: one receiving 40 mg of adalimumab-bwwd every other week and the other receiving a placebo. The graph shows an increase in response for the treatment group compared to the placebo throughout the study period up to 52 weeks.*

FDA Label Image

Figure 2 (Image 02)

A line graph comparing the percentage of ASA 20 response over time (weeks) between Adalimumab (N=208) and placebo (N=107). The graph shows response percentages on the y-axis and time in weeks on the x-axis, depicting higher response rates for Adalimumab throughout the 24-week period.*

FDA Label Image

Samsung Logo (Image 03)

FDA Label Image

Figure A (Prefilled Syringe)

An instructional diagram labeled Figure A, showing a subcutaneous injection device for Adalimumab-bwwd solution. The syringe components are labeled from left to right: needle cap, body with window, flange, and plunger, illustrating parts of the delivery system.*

FDA Label Image

Refrigerator (Image 08)

Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection, presented in a carton and a prefilled syringe. The labeler is Cordavis Limited. The syringe is marked with dosage and usage information visible.*

FDA Label Image

Light (Image 09)

Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection vial label shows the brand name and strength prominently. The label includes the medication name, concentration, dosage form, route of administration, and the labeler Cordavis Limited. The vial label is mostly white with blue and gray text and includes storage and usage instructions in smaller print.*

FDA Label Image

Caution (Image 10)

The image shows a vial label for Adalimumab-bwwd solution, 40 mg/0.4 mL, a human prescription drug for subcutaneous use. The label includes the product name, concentration, and references Cordavis Limited as the labeler. Additional standard vial information and text are visible but not fully legible.*

FDA Label Image

Container (Image 11)

Adalimumab-bwwd 40 mg/0.4 mL subcutaneous solution packaging label by Cordavis Limited. The label includes product name, strength, dosage form, labeler information, and usage instructions, with a barcode at the bottom. The design features blue and white colors with text in black.*

FDA Label Image

Figure B (Prefilled Syringe)

An instructional illustration showing a wrist with a pink watch displaying time, alongside a syringe filled with solution, likely depicting timing or preparation related to subcutaneous injection of a medication.*

FDA Label Image

Figure C (Prefilled Syringe)

An instructional illustration showing a prefilled syringe, an alcohol swab packet labeled 70% isopropyl, a red sharps container labeled for disposal, and several cotton balls or gauze pads included in the carton. This diagram likely depicts components provided with Adalimumab-bwwd 40 mg/.4 mL solution for subcutaneous injection.*

FDA Label Image

Figure D (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe filled with a liquid solution. Three check points are highlighted near the syringe: 'Clear?', 'No particles?', and 'Check expiration date?'. This diagram emphasizes visual inspection steps before administering the solution.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration labeled Figure E showing application sites on an unclothed male torso and upper legs for subcutaneous injection. The image includes a reminder to clean the skin and depicts an alcohol swab packet labeled 70% isopropyl.*

FDA Label Image

Figure F (Prefilled Syringe)

An instructional illustration showing two hands holding a syringe, with one hand removing the syringe cap by pulling it off in the direction indicated by a blue arrow.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration showing the method of subcutaneous injection at a 45-degree angle into the skin using a syringe. The image demonstrates hand positioning and the injection angle, labeled as 45 degrees, likely to guide proper administration technique.*

FDA Label Image

Figure H (Prefilled Syringe)

An instructional illustration showing the use of a subcutaneous injection device. A hand holds a syringe labeled with an arrow at the plunger, positioned to inject the solution into the skin on the finger of the other hand.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional diagram showing the proper way to complete a subcutaneous injection with Adalimumab-bwwd solution. It illustrates a hand holding the injection device with needle retracted, emphasizing that no medicine should leak out except for a small drop. A sharps container is shown for safe disposal of the used device.*

FDA Label Image

Samsung Logo (Image 20)

FDA Label Image

Figure A (Autoinjector)

An illustration labeled Figure A depicting a subcutaneous injection device for Adalimumab-bwwd. It shows parts including the needle cap, base, medicine window, and medicine label, highlighting components of the solution injection device.*

FDA Label Image

Refrigerator (Image 23)

The image shows the packaging label for Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection. The label includes the proprietary name, strength, and dosage form. The labeler is Cordavis Limited. The packaging appears to be a carton with blue and white colors and includes additional text and graphics.*

FDA Label Image

Light (Image 24)

Adalimumab-bwwd 40 mg/.4 mL solution for subcutaneous injection in a 1 mL clear glass vial with a purple flip-off cap and aluminum seal. The vial label includes product name, concentration, and manufacturing information by Cordavis Limited.*

FDA Label Image

Caution (Image 25)

The image shows a medication label for Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous use. The label includes the product name, strength, dosage form, and the labeler, Cordavis Limited. The label likely belongs to a vial or syringe container for human prescription drug use.*

FDA Label Image

Container (Image 26)

Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection in a prefilled syringe. The label includes the product name, strength, dosage form, and manufacturer Cordavis Limited. The syringe is partially visible within the packaging, with dosage markings readable.*

FDA Label Image

Figure B (Autoinjector)

Illustration showing a human hand wearing a pink wristwatch and holding a prefilled syringe or injector pen, likely depicting timing or administration guidance for a subcutaneous injection.*

FDA Label Image

Figure C (Autoinjector)

An instructional illustration showing an autoinjector device labeled as Adalimumab, accompanied by images of an alcohol swab, a sharps container, and cotton balls or gauze. The text notes that the alcohol swab, sharps container, and cotton ball or gauze are not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

An instructional illustration showing a hand holding a syringe-like device, highlighting important checks before use: ensuring the solution is clear without particles and verifying the expiration date on the syringe. The image emphasizes safety and quality checks for subcutaneous injectable medication.*

FDA Label Image

Figure E (Autoinjector)

Illustration showing recommended subcutaneous injection sites on the human body, including the abdomen and front of the thighs. The image advises cleaning the skin before injection using an alcohol swab labeled 70% isopropyl.*

FDA Label Image

Figure F (Autoinjector)

Illustration showing a hand removing a green cap from a prefilled syringe, indicated by a left-pointing blue arrow, demonstrating part of the preparation process for subcutaneous injection.*

FDA Label Image

Figure G (Autoinjector)

Illustration showing a hand holding an injection pen for subcutaneous administration. The diagram demonstrates pressing the pen downward until a clicking sound is heard, indicating proper activation or injection.*

FDA Label Image

Figure H (Autoinjector)

An instructional illustration showing a hand gripping a syringe device vertically with the thumb pressing on an activation area marked in yellow, accompanied by the word 'Click' to indicate auditory or tactile feedback during subcutaneous injection preparation or administration.*

FDA Label Image

Figure I (Autoinjector)

An instructional illustration showing a hand holding a syringe with a yellow medicine window, indicating a correct dose when no medicine has leaked out. A labeled sharps container is also shown, indicating proper disposal of the syringe.*

FDA Label Image

Samsung Logo (Image 35)

FDA Label Image

Figure A (Prefilled Syringe)

An instructional diagram labeled Figure A illustrates a syringe with parts identified, including needle cap, body with window, flange, and plunger. The syringe is shown in a side view with each component clearly demarcated.*

FDA Label Image

Refrigerator (Image 38)

The image shows the packaging label for Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection. The label includes the product name, strength, dosage form, and route. The labeler is Cordavis Limited. The layout features text and design elements consistent with a prescription drug package.*

FDA Label Image

Light (Image 39)

Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection, supplied in a single-use prefilled syringe. The label shown includes the Cordavis Limited name and features red and gray design elements on a white background.*

FDA Label Image

Caution (Image 40)

Adalimumab-bwwd 40 mg/.4 mL subcutaneous solution vial. The label displays the proprietary and generic names, strength, dosage form, and route of administration. Cordavis Limited is listed as the labeler. The label includes dosing information and barcode details in a compact format on a yellow background.*

FDA Label Image

Container (Image 41)

Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection packaging label from Cordavis Limited. The label features the product name, strength, dosage form, and labeler information clearly. The design includes a white and green color scheme with text detailing the product type and administration route.*

FDA Label Image

Figure B (Prefilled Syringe)

An illustration showing a wrist wearing a watch and a subcutaneous injection device nearby, likely depicting timing or administration instructions for a subcutaneous solution drug.*

FDA Label Image

Figure C (Prefilled Syringe)

An instructional illustration labeled Figure C showing a prefilled syringe, an alcohol swab packet, a red sharps container, and a small cotton ball or gauze pad, with a note that the alcohol swab, sharp container, and cotton ball or gauze are not included in the carton.*

FDA Label Image

Figure D (Prefilled Syringe)

An instructional illustration labeled Figure D showing a hand holding a syringe with solution. The diagram highlights checking the solution for clarity, absence of particles, and verifying the expiration date before use.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration showing a human torso and upper legs with a highlighted abdominal area and thighs. It includes an image of an alcohol swab packet labeled 70% isopropyl and a reminder to clean the skin before injection. The diagram likely relates to subcutaneous injection sites for Adalimumab-bwwd solution.*

FDA Label Image

Figure F (Prefilled Syringe)

An instructional illustration showing two hands preparing a syringe by removing or attaching a needle cap. The left hand holds the needle cap while the right hand holds the syringe, indicating a step in the process of readying a subcutaneous injection for use.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration labeled 'Figure G' showing a hand holding a syringe at a 45-degree angle to the skin on the opposite arm, demonstrating the proper injection angle for subcutaneous administration.*

FDA Label Image

Figure H (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe for subcutaneous injection, positioned to inject into the forearm. The image highlights proper finger placement on the syringe plunger.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe above a labeled sharps container. The image includes text advising to discard the syringe if the needle is retracted and no medicine has leaked out, with an indication that a small drop is acceptable.*

FDA Label Image

Samsung Logo (Image 50)

FDA Label Image

Figure A (Autoinjector)

Illustration labeled Figure A showing a subcutaneous injection device for Adalimumab-bwwd, 40 mg/.4mL solution. The diagram identifies parts of the device including the needle cap, base, medicine window, and medicine label.*

FDA Label Image

Refrigerator (Image 53)

The image shows the packaging label for Adalimumab-bwwd, a 40 mg/0.4 mL subcutaneous solution. The packaging is a small box primarily in white and blue, with the proprietary name Adalimumab-bwwd and strength shown prominently. The labeler, Cordavis Limited, is also indicated.*

FDA Label Image

Light (Image 54)

The image shows a vial labeled Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection. The label also includes the generic name adalimumab-bwwd and indicates it is a human prescription drug. The vial is small and amber-colored with a white and blue cap, and the labeler is Cordavis Limited.*

FDA Label Image

Caution (Image 55)

The label displays Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection from Cordavis Limited. The image shows a rectangular product container label with the proprietary name and strength clearly printed, along with usage and manufacturer details.*

FDA Label Image

Container (Image 56)

Adalimumab-bwwd 40 mg/0.4 mL solution for subcutaneous injection in a single-use prefilled syringe. The label displays usage instructions and dosage information. The product is labeled by Cordavis Limited and intended as a human prescription drug.*

FDA Label Image

Figure B (Autoinjector)

An instructional illustration showing a wristwatch with a countdown timer set to 15 or 30 minutes and an injection pen device, likely for subcutaneous administration. The image appears to demonstrate timing related to the use of the injection pen.*

FDA Label Image

Figure C (Autoinjector)

Illustration showing components related to Adalimumab-bwwd administration, including an autoinjector pen for subcutaneous injection, an alcohol swab, a sharps container, and cotton balls or gauze. Text notes that alcohol swab, sharps container, and cotton or gauze are not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

An instructional illustration showing a hand holding a prefilled syringe labeled '40 mg/0.4 mL solution for injection.' The image highlights three key steps: checking the syringe for particles and clarity, verifying the expiration date, and preparing for subcutaneous injection.*

FDA Label Image

Figure E (Autoinjector)

An instructional illustration showing a bare torso and upper legs of a person with marked areas on the abdomen and front thighs, indicating recommended injection sites. An alcohol swab package labeled "Alcohol Swab 70% Isopropyl" is also depicted, emphasizing the need to clean skin before injection.*

FDA Label Image

Figure F (Autoinjector)

An instructional illustration showing two hands preparing a prefilled injection pen by removing its cap. The left hand holds the cap being pulled off, indicated by a leftward arrow, while the right hand holds the pen device horizontally. This image demonstrates how to ready the pen for subcutaneous injection.*

FDA Label Image

Figure G (Autoinjector)

An instructional illustration showing a hand holding a syringe with the needle pointed downward, positioned above the skin to demonstrate the subcutaneous injection technique. The image includes an arrow indicating downward injection and a 'Click' symbol suggesting activation or locking of the injection device before administration.*

FDA Label Image

Figure H (Autoinjector)

An instructional illustration showing a hand holding a syringe or injector for subcutaneous injection, with a zoomed-in inset highlighting a feature labeled 'Click.' The image likely demonstrates proper injection technique or the confirmation of correct device activation.*

FDA Label Image

Figure I (Autoinjector)

An instructional illustration showing a hand holding a prefilled syringe, with a yellow medicine window indicating the dose has been received. Text instructions highlight that a yellow medicine window and no medicine leakage (small drops allowed) confirm dose delivery, with a sharps container nearby for disposal.*

FDA Label Image

Samsung Logo (Image 65)

FDA Label Image

Pdp (Single-dose Prefilled Syringe Carton 40 mg/0.4 mL)

Packaging label for Adalimumab-bwwd injection 40 mg/0.4 mL in a single-dose prefilled syringe. The carton contains 2 single-dose prefilled syringes and includes a medication guide and instructions for use. Manufactured for Cordavis Limited, Dublin, Ireland, and by Samsung Biologics Co., Ltd., Korea. Storage and usage information is provided on the label.*

FDA Label Image

Pdp (Single-dose Autoinjector Carton 40 mg/0.4 mL)

Packaging label for Adalimumab-bwwd injection 40 mg/0.4 mL, a single-dose prefilled autoinjector for subcutaneous use. Label shows product name, strength, dosage form, and that it contains 2 single-dose prefilled autoinjectors. Manufactured for Cordavis Limited and by Samsung Biologics Co., Ltd. Includes storage instructions, hotline number, ingredients, and safety warnings. Product of Korea.*

FDA Label Image

Figure 3 (Image 72)

Two line graphs depicting treatment failure rate (%) over a 20-month period for placebo and adalimumab treatments. The top graph is labeled Study UV I and the bottom graph Study UV II, showing treatment failure rates with placebo generally higher than adalimumab. Number of patients at risk is noted below the x-axis for both treatment groups over time.*

FDA Label Image

Cordavis Logo (Image 73)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.